加载中
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
前收盘价
US$14.41
+US$0.41 · +2.93%
盘中时间采用ET。市场数据可能有所延迟。
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
日内区间
当前US$14.41
52周区间
当前US$14.41
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
32
偏贵
情绪
50
多空交织
风险
47
风险偏高
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
日内区间
当前US$14.41
52周区间
当前US$14.41
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 123.2万 USD | — | — | — | — |
| 毛利 | −123.2万 USD | — | — | — | — |
| 研究与开发 | 3083.3万 USD | 2702万 USD | 2642.4万 USD | 2089万 USD | 1144.7万 USD |
| 销售、一般及管理费用 | 1022.3万 USD | 902.2万 USD | 925.6万 USD | 1124.6万 USD | 234.3万 USD |
| 营业费用 | 4105.6万 USD | 3604.2万 USD | 3568万 USD | 3213.6万 USD | 1379万 USD |
| 利息收入 | 383.7万 USD | 427.7万 USD | 483万 USD | 179万 USD | 21.1万 USD |
| 利息支出 | 41.9万 USD | 30.3万 USD | 7.5万 USD | — | — |
| 折旧和摊销 | 123.2万 USD | 110.2万 USD | 107.4万 USD | 97.9万 USD | 77.6万 USD |
| 营业利润 | −4228.8万 USD | −3604.2万 USD | −3568万 USD | −3213.6万 USD | −1379万 USD |
| 净利润 | −4262.7万 USD | −3175万 USD | −2915.7万 USD | −3376.2万 USD | −2727.1万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
iShares Core MSCI EAFE ETFIEFA659.32万0.00%1894.71亿 USD0.07%US$96.52+0.68%
iShares MSCI EAFE Small-Cap ETFSCZ309.17万0.02%128.85亿 USD0.40%US$83.93+0.82%
ARK Israel Innovative Technology ETFIZRL258.13万1.98%1.37亿 USD0.49%US$28.36+1.61%
iShares MSCI Israel ETFEIS186.62万0.22%8.6亿 USD0.59%US$118.28+0.54%
iShares Core MSCI Total International Stock ETFIXUS87.51万0.00%586.25亿 USD0.07%US$94.99+0.90%
State Street SPDR S&P International Small Cap ETFGWX52.92万0.06%9.08亿 USD0.40%US$45.56+0.93%
Fidelity Nasdaq Composite Index ETFONEQ44.08万—109.4亿 USD0.21%US$107.81+0.63%
Even Herd Long Short ETFEHLS34.98万0.60%5883.5万 USD2.62%US$25.4482+0.28%iShares Core MSCI EAFE ETFIEFAiShares MSCI EAFE Small-Cap ETFSCZARK Israel Innovative Technology ETFIZRLiShares MSCI Israel ETFEISiShares Core MSCI Total International Stock ETFIXUSState Street SPDR S&P International Small Cap ETFGWXFidelity Nasdaq Composite Index ETFONEQEven Herd Long Short ETFEHLSAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
